Hims, Hers and food and drug administration

Hims & Hers can't sell off-brand Ozempic forever, but it can still sell these weight-loss meds
Hims & Hers (HIMS) made a killing last year selling an off-brand version of Ozempic, but with the drug’s shortage now over, the company will soon have to halt sales of its cheaper alternative. That said,
Hims & Hers tumbles 27% as investors fear uncertainty without compounded weight-loss drugs
Hims & Hers stock tumbled after the company confirmed it would stop selling some compounded weight-loss drugs.
Hims & Hers warns it may stop selling compounded weight-loss drugs
Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo Nordisk because its pathway to do so closed when the U.S. FDA declared Friday that the drug's shortage was over.
Ozempic and Wegovy shortage ends, setting up weight loss drug showdown
Ozempic and Wegovy, the popular GLP-1 drugs for diabetes and weight loss, are no longer in short supply, the FDA declared Friday. Why it matters: That's good news for Novo Nordisk (whose stock rose 5% Friday) and potentially bad news for Hims & Hers (which fell 26%).
Hims & Hers Stock Drops as FDA Says Ozempic and Wegovy No Longer in Short Supply
Key Takeaways Hims & Hers Health shares swooned after the Food & Drug Administration said the active ingredient in Ozempic and Wegovy is no longer in short supply.The company makes compounded versions of weight-loss drugs under an FDA rule that applies when the originals are difficult to obtain.
Hims Stock Crashes After FDA Resolves Weight-Loss Drugs Shortage
Hims stock dropped sharply Friday after the U.S. Food and Drug Administration said the shortage of widely-used weight-loss and diabetes drugs has been resolved. The FDA website indicated that the shortage of Novo Nordisk's Ozempic and Wegovy has ended.
ConsumerAffairs1h
Hims & Hers withdraws from Wegovy, Ozempic market
Hims & Hers is stopping its sales of an alternative to blockbuster weight-loss drugs Wegovy and Ozempic. That follows the U.S ...
Hims & Hers Health Analyst Sees Buying Opportunity Following Steep Selloff: 'We See No Reason To Change Our View'
Hims & Hers Health Inc. (NYSE: HIMS) shares dropped sharply after the company reported its fourth-quarter earnings. Here's ...
WCPO Cincinnati4h
Hims and Hers likely to stop selling cheaper versions of GLP-1 medications
The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...
STAT5h
Lilly expands its Zepbound vial offering, as Hims pulls back on semaglutide
Lilly expands its Zepbound vial offering, as HIMS pulls back on semaglutide, and other biotech news in today's Readout ...
Hims & Hers Health: Focus On The Future, Not GLP-1s
Hims & Hers Health, Inc. showcases strong growth with diverse revenue streams. Discover why its stock dip offers a unique opportunity. Learn more on HIMS stock here.
BioPharma Dive3h
Drug compounders sue FDA over declaration ending Wegovy shortage
Telehealth provider Hims & Hers said it will tell consumers they need to seek “alternative options on the commercial dosing,” ...
24/7 Wall St4h
HIMS Stock Craters - Is It a Buying Opportunity?
Shares of Hims & Hers Health (NASDAQ:HIMS) continued to meltdown Tuesday in noontime trading after the direct-to-consumer healthcare platform said it couldn’t guarantee it would be able to continue ...
Hims & Hers: Capitalizing On The GLP-1 Rush Before The Window Closes (Rating Upgrade)
Hims & Hers projects $725M in GLP-1 weight loss revenue for 2025, a 3.2x increase from 2024. Read why I upgrade HIMS stock ...
Investor's Business Daily on MSN5h
IBD 50's No. 2, Hims & Hers, Crashes 15% Despite Upbeat Earnings
Compounding pharmacy and IBD 50 newcomer Hims & Hers Health reported bullish earnings and sales growth late Monday. But Hims ...